Enterprise Value
779.2M
Cash
207.4M
Avg Qtr Burn
-24.79M
Short % of Float
13.16%
Insider Ownership
0.18%
Institutional Own.
95.76%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) Details Essential tremor Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
PRAX-628 Details Epilepsy, Focal Onset Seizures | Phase 2b Initiation | |
Ulixacaltamide (PRAX-944) (T-type calcium channel blocker) Details Parkinson's disease | Phase 2 Data readout | |
PRAX-562 Details Developmental and Epileptic Encephalopathy | Phase 2 Data readout | |
PRAX-222 Details Developmental and Epileptic Encephalopathy | Phase 1/2 Data readout | |
PRAX-114 (GABAA receptor PAM) Details Perimenopausal Depression | Failed Discontinued | |
PRAX-114 (GABAA receptor PAM) Details Major depressive disorder | Failed Discontinued |